Document is current

Article History

Received: 17 October 2023

Accepted: 1 December 2023

First Online: 12 December 2023

Declarations

:

: Not applicable.

: A. O: Consultant fee from NMS. Former consultant of Servier, WWIT and CancerAppy. Former employee of Symphogen. V. M: reports personal fees from Bristol-Myers Squibb, Bayer, Janssen, and Pieris outside the submitted work. P. P: Consultant for: Bristol-Myers Squibb, Merck, MSD. Speaker’s Bureau for Bristol-Myers Squibb, Merck, MSD. Employee of: None. Grant/Research support from (Clinical Trials): Bristol-Myers Squibb, AstraZeneca, MSD. Travel Academic work Fees from: Merck, MSD and Bristol-Myers Squibb. E. C. reports grants and personal fees from Astellas, Novartis, Nanobiotix, Pfizer, Janssen-Cilag, PsiOxus Therapeutics, Merck, Bristol-Myers Squibb, Seattle Genetics, Boehringer Ingelheim, AstraZeneca, Roche/Genentech, Servier, Celgene, AbbVie, Amcure, Alkermes, PharmaMar, and BeiGene, personal fees from GLG, Medscape, Gilead, Pierre Fabre, Cerulean Pharma, EUSA, Gehrmann Consulting, Guidepoint, and OncoDNA, and grants from ACEO, Adaptimmune, AMGEN, CytomX, GlaxoSmithKline, H3,Incyte, Kura, Lilly, Nektar, Loxo, MacroGenics, Menarini, Merus, Principia, PUMA, Sanofi, Taiho, Tesaro, Transgene, Takeda, Inovio, MSD, Mersana Therapeutics, Daiichi Sankyo, ORCA, Boston Therapeutics, Dynavax Technologies, Debiopharm, Regeneron, Millennium, Synthon, Spectrum, and Rigontec outside the submitted work. F. M: Former employee of Entrechem. Employee of CancerAppy. No competing interests to declare in relation to this work.